Reuters logo
3 个月前
BRIEF-Denovo Biopharma obtains exclusive license to Liafensine from AMRI
2017年4月24日 / 上午11点20分 / 3 个月前

BRIEF-Denovo Biopharma obtains exclusive license to Liafensine from AMRI

1 分钟阅读

April 24 (Reuters) - Denovo Biopharma:

* Denovo Biopharma obtains exclusive license to Liafensine from AMRI

* Denovo Biopharma - under terms, Denovo Biopharma gains an exclusive license to all rights to develop, manufacture and commercialize Liafensine globally

* Denovo Biopharma - Liafensine was well tolerated, with no evidence of dose-dependent discontinuations due to adverse events

* Denovo Biopharma - Liafensine program was not continued beyond phase 2 studies Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below